NEW YORK, June 16, 2021 (GLOBE NEWSWIRE) — WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Kindred Biosciences, Inc. (“Kindred” or the “Company”) (NASDAQ: KIN) in connection with the proposed acquisition of the Company by Elanco Animal Health Incorporated (NYSE: ELAN). Under the terms of the merger agreement, the Company’s shareholders will receive $9.25 per share in cash for each share of Kindred common stock that they hold. The transaction is valued at approximately $440 million.
If you own Kindred shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
Or please contact:
Joshua Rubin, Esq.
1500 Broadway, 16th Floor
New York, NY 10036
WeissLaw LLP is investigating whether (i) Kindred’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $9.25 per-share merger consideration adequately compensates Kindred’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.
WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]